During the Late-Breaking News Session on
This clinical trial evaluated the safety, tolerability, pharmacokinetics and immunogenicity of intravenous or subcutaneous KPL-716 in healthy volunteers and subjects with moderate-to-severe atopic dermatitis experiencing moderate-to-severe pruritus. Atopic dermatitis served as a proxy for IL-31-driven pruritic diseases as a means to assess target engagement and a potential early signal of efficacy in reducing pruritus.
KPL-716 is an investigational fully-human monoclonal antibody that targets oncostatin M receptor beta (OSMRβ), which mediates signaling of IL-31 and oncostatin M (OSM), two key cytokines implicated in pruritus, inflammation and fibrosis. Kiniksa believes KPL-716 to be the only monoclonal antibody in development that targets both pathways simultaneously.
Kiniksa is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Kiniksa has a pipeline of product candidates across various stages of development, currently focused on autoinflammatory and autoimmune conditions. For more information, please visit www.kiniksa.com.
Every Second Counts!™
Kiniksa Investor and Media Contact
Source: Kiniksa Pharmaceuticals, Ltd.